Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

Lorenza Romani; Francesca Ippolita Calò Carducci; Sara Chiurchiù; Laura Cursi; Maia De Luca; Martina Di Giuseppe; Andrzej Krzysztofiak; Laura Lancella; Paolo Palma; Leonardo Vallesi; Tiziana Corsetti; Andrea Campana; Emanuele Nicastri; Paolo Rossi; Stefania Bernardi

doi:10.3390/children9030369

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

Children (Basel). 2022 Mar 7;9(3):369. doi: 10.3390/children9030369.

Authors

Lorenza Romani¹, Francesca Ippolita Calò Carducci¹, Sara Chiurchiù¹, Laura Cursi¹, Maia De Luca¹, Martina Di Giuseppe¹, Andrzej Krzysztofiak¹, Laura Lancella¹, Paolo Palma^{2

3}, Leonardo Vallesi⁴, Tiziana Corsetti⁴, Andrea Campana⁵, Emanuele Nicastri⁶, Paolo Rossi^{3

7}, Stefania Bernardi¹

Affiliations

¹ Immunology and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
² Research Unit of Congenital and Perinatal Infections, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
³ Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
⁴ Hospital Pharmacy Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
⁵ Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
⁶ National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy.
⁷ Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.

Abstract

Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old.

Keywords: COVID-19; children; monoclonal antibody.